Target |
Mechanism 5-HT3 receptor antagonists [+1] |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism 5-HT3 receptor agonists |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism AChR antagonists |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Oct 2007 |
Sponsor / Collaborator |
Start Date01 Nov 2005 |
Sponsor / Collaborator |
Start Date01 Sep 2005 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Oxybutynin/Gabapentin ( nAChRα1/β1/δ/γ ) | Urinary Bladder, Overactive More | Discontinued |
MCI-225 ( 5-HT3 receptor x NET ) | Vomiting More | Discontinued |
Pumosetrag ( 5-HT3 receptor ) | Gastroesophageal Reflux More | Pending |